FindTrial
Sign In

Immunogenomic dynamics and biomarkers in patients with hepatocellular carcinoma receiving immunotherapy

Immunogenomic dynamics and biomarkers in patients with unresectable hepatocellular carcinoma receiving immunotherapy-based treatments

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0005305
Enrollment
50
Registered
2020-08-11
Start date
2020-09-28
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Asan Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Patients with histologically confirmed HCC, 2) Patients with histologically confirmed locally advanced, recurrent or metastatic HCC, which was judged not to be eligible for surgical resection, liver transplantation or radiofrequency ablation 3) Patients who will receive immuno-oncology treatment

Exclusion criteria

Exclusion criteria: 1) Patients with histologically confirmed fibrolamellar type HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC 2) Patients with concurrent other malignancy 3) Patients who are candidates for local curative treatments such as hepatic resection, liver transplantation, or radiofrequency ablation 4) Patients who have a possibility of confusion in the results of the clinical research

Design outcomes

Primary

MeasureTime frame
treatment response—

Secondary

MeasureTime frame
Overall survival—

Countries

Korea, Republic of

Contacts

Public ContactJu Hyun Shim

Asan Medical Center

s5854@amc.seoul.kr+82-2-3010-3190

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026